Audited Results for the year 31.03.2025
FISCHER · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fischer Medical Ventures (formerly Fischer Chemic) reported audited FY25 results with a clean (unmodified) audit opinion from Bilimoria Mehta & Co. On a consolidated basis, revenue from operations surged to Rs. 11,069.87 lakhs from Rs. 2,098.13 lakhs in FY24 — a jump of over 5x, driven by newly added subsidiaries. However, consolidated profit after tax fell to Rs. 120.79 lakhs from Rs. 183.79 lakhs due to share of losses from associates and higher expenses. On a standalone basis, revenue declined sharply to Rs. 521.97 lakhs from Rs. 1,152.83 lakhs, but standalone PAT improved to Rs. 66.32 lakhs from Rs. 40.28 lakhs. The Board recommended a final dividend of Rs. 0.05 per share, re-appointment of the statutory auditor for a second 5-year term, and recommended listing on the NSE Main Board.
Strong consolidated revenue growth signals business expansion through subsidiaries, but declining consolidated profitability and negative standalone operating cash flow (-Rs. 2,280.64 lakhs) may temper investor enthusiasm. The proposed NSE listing could improve liquidity and visibility, while the modest dividend indicates conservative cash distribution.